Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area.

If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of Osteoarthritis (OA) through their repurposed drug Zilosul.

PAR surged by an impressive 253% YTD. Meaning if you invested $10,000 in January 2019 and sold today you would have come out with $25,300.

Screenshot (17)

Paradigm started on the watchlist of investors in 2019. However, PAR’s successful clinical trials, FDA approval and significant improvement in financials resulted in a 300% rise throughout last year.

The bullish direction has made a good entry point for PAR unlikely. However, with the coronavirus driving markets down a good entry point for PAR could be possible with  your own research.

The coronavirus has made PAR’s share price over the last week volatile.

Screenshot (19)

 

 

Paradigm’s 2020 Key Price Sensitive Events (PSE’s)

Screenshot (23)

It can be argued that PAR is still in the early stages of development. By looking at the table above Paradigm is overloaded with Price Sensitive Events (PSE’s) in 2020. Despite the endless list, it is worth focusing your attention the four events in bold.Why? Because a release of positive media news could trigger a significant surge in the share price.

 

Is PAR worth watching in the next few weeks?

You must consider:

  • Does PAR’s 2020 calendar present enough PSE’s to trigger an upward shift in share price?
  • Is a good entry point of say $3.75-$3.95 possible in the upcoming weeks?
  • Do I understand how the business makes money or why they don’t now, and do I like PAR’s business model?

If you can answer yes to all three and conduct your own research PAR might be worth the investment. The entry points above are not to be used as advice. The entry point you use must include your investment interests.

 

Why not broaden your knowledge of the biotech/pharmaceutical industry by reading our free, extensive and uncomplicated analysis of Opthea (ASX:OPT), Imugene Ltd (ASX:IMU) or Novetia Helathcare (ASX:NHL).

Here is our free, uncomplicated, and extensive ASX portfolio

https://youth-investment-group.com/portfolio/

 

Here are some of Youth Investment Group’s best articles:

Why a company invested 28 million into PointsBet Holdings ? Or

How investing 40k in Tesla at IPO would make you a millionaire or

Understanding the cannabis trends in 2019.

 

If you enjoy our articles or are wanting to learn more, you can subscribe to us for free via email and get updates when we post new articles. From all of us at YIG, thank you for the support.

The information above should not be taken as financial advice. Youth Investment Group has no liability for personal financial interests or investment decisions. You should make your own investment decisions based upon your own research and what you believe is best for you.

 

Written by Patrick McLoughlin, Associate of YIG.

Leave a comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.